LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 303 participants.

Also called NCT02964247

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 303 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02964247
Other papers using this trial's data
  • Liraglutide as add-on to sodium-glucose co-transporter-2 inhibitors in patients with inadequately controlled type 2 diabetes: LIRA-ADD2SGLT2i, a 26-week, randomized, double-blind, placebo-controlled trial Diabetes, obesity & metabolism, 2020-06 DOI, PubMed 31984646, PMC7317838 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Brazil, India, Israel, Puerto Rico, Russia, United Arab Emirates (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02964247. Randomized; double masking; primary purpose treatment. Start 2017-03-03 (actual); primary completion 2018-05-04 (actual). Results posted on 2019-07-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
LIRA-ADD2SGLT2i - Liraglutide Versus Placebo as add-on to SGLT2 Inhibitors.
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
liraglutide
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02964247
Content hash
27a01cf1b636395340edeeed70237abb0937a0eccce515f5cd49dea9b8b23b31